SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Torrent Pharma tumbles on reporting 59% fall in Q2 consolidated net profit

27 Oct 2016 Evaluate

Torrent Pharmaceuticals is currently trading at Rs. 1418.75, down by 147.10 points or 9.39% from its previous closing of Rs. 1565.85 on the BSE.

The scrip opened at Rs. 1490.00 and has touched a high and low of Rs. 1494.00 and Rs. 1400.20 respectively. So far 38830 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1767.80 on 25-Aug-2016 and a 52 week low of Rs. 1190.00 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 1640.95 and Rs. 1560.00 respectively. The current market cap of the company is Rs. 24046.55 crore.

The promoters holding in the company stood at 71.25%, while institutions and non-institutions held 18.16% and 10.60% respectively.

Torrent Pharmaceuticals has reported 75.26% fall in its net profit at Rs 169 crore for the quarter under review as compared to Rs 683 crore for the same quarter in the previous year. Total income of the company decreased by 32.99% at Rs 1117 crore for the quarter under review as compared Rs 1667 crore for the corresponding quarter previous year.   

On the consolidated basis, the company has reported 59.33% fall in its net profit after taxes, minority interest and share of profit of associates of Rs 207 crore for the quarter ended September 30, 2016 as compared to Rs 509 crore for the same quarter in the previous year. The total income of the company decreased by 16.55% at Rs 1472 crore for quarter under review as compared to Rs 1764 crore for the quarter ended September 30, 2015.

Torrent Pharma Share Price

4178.85 22.50 (0.54%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×